24th Jan 2017 07:00
For immediate release
| 24 January 2017 |
Quantum Pharma Plc
('Quantum' or the 'Company')
Grant of Options
Further to the announcement on 11 November 2016, Quantum Pharma plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that, upon his commencing employment with the Company on 23 January 2017, it granted options over 1,100,000 Ordinary Shares of 10 pence each ('Ordinary Shares') with an exercise price of 30 pence, to Gerard Murray, Chief Financial Officer.
The options represent approximately 0.65% of the current issued share capital and are in accordance with the rules of the Quantum Long Term Incentive Plan ('LTIP') 2014 as amended by the Remuneration Committee. The options shall vest and become exercisable at an exercise price of 30 pence, either on the mid-market closing share price being greater than 140 pence for an average of 90 days or on a change of control. The options shall lapse if the target has not been achieved on or before 31 December 2021 and the exercise period runs from the vesting date until 9 November 2026.
Following this award, Gerard Murray has an interest in 200,000 Ordinary Shares and options over 1,100,000 Ordinary Shares, representing 0.12% and 0.65% respectively of the current share capital.
Following the above LTIP grant and other recent grants of LTIP options (on the same terms as above) and lapses of existing LTIP options, there are outstanding options over 15,940,438 Ordinary Shares, representing approximately 9.43% of the current issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Gerard Murray | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Financial Officer | ||||
b)
| Initial notification /Amendment | Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Quantum Pharma Plc | ||||
b) | LEI | (Pending) | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument Identification code | Options over Ordinary Shares of £0.10
QP. ISIN: GB00BRTL8Q42 | ||||
b) | Nature of the transaction | Grant of options | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A - single transaction | ||||
e) | Date of the transaction | 23 January 2017 | ||||
f) | Place of the transaction | n/a | ||||
d) | Aggregated information - Aggregated volume - Price | N/A - single transaction | ||||
e) | Date of the transaction | 23 January 2017 | ||||
f) | Place of the transaction | Off market | ||||
- Ends -
For further information:
Quantum Pharma Plc | |
Chris Rigg, CEO Gerard Murray, CFO Craig Swinhoe, Group Strategic Projects Director and Company Secretary | Tel: +44 (0) 1207 279 404 www.quantumpharmaplc.com |
N+1 Singer (NOMAD and Broker) | Tel: +44 (0) 20 7496 3000 |
Sandy Fraser / Nick Owen / James White | www.n1singer.com |
Media enquiries: | |
Buchanan | |
Henry Harrison-Topham / Sophie Cowles / Steph Watson | Tel: +44 (0) 20 7466 5000 |
www.buchanan.uk.com |
Notes to Editors
Quantum Pharma is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions - Specials, Niche Pharmaceuticals and Medication Adherence - offering a portfolio of innovative and complementary products and services.
For further information, please visit www.quantumpharmagroup.com.
Related Shares:
Quantum Pharma